Corning Dodges EU Antitrust Clash With ‘Gorilla Glass' Deal
The European Commission said in a statement on Friday that the US glass firm had agreed to 'waive all exclusive dealing clauses in all its current agreements' in order to allay EU concerns.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
a minute ago
- The Hill
Trump's new model to support Ukraine is a win-win
From the start, Ukraine's defense against Russia's full-scale invasion has been underpinned by a robust commitment from its Western partners. The Biden administration's pledge to support Ukraine 'as long as it takes' promised a sustained flow of military and financial aid directly from Washington. This 'direct donor' model was key to Ukraine's initial resilience, providing essential weaponry from U.S. stockpiles. Biden's approach primarily involved direct transfers from U.S. weapons inventories, prioritizing speed and ensuring that Ukraine received vital equipment quickly to counter Russian aggression. The American government provided extensive amounts of equipment, from air-defense missiles to artillery rounds and armored vehicles, directly to Kyiv. Now, under President Trump, the paradigm is shifting. The U.S. is transitioning from a direct donor to a 'strategic supplier,' where European allies purchase American weapons for Ukraine at their own expense. While this reorientation marks a significant change, it is far from the worst-case scenario for Ukraine. Instead, it represents a pragmatic and potentially more sustainable evolution of transatlantic burden-sharing, securing critical capabilities for Ukraine while invigorating the U.S. defense industrial base and recalibrating the nature of allied support. Support is still 'as long as it takes' but also 'at the others' expense.' This marks a departure from the traditional post-World War II donor-recipient model, particularly within the NATO alliance, towards a more transactional 'America First' approach. Future U.S. engagement in global security will likely be contingent upon tangible economic benefits and direct cost-sharing from allies. Such a shift could lead to a more predictable, albeit less altruistic, framework for security cooperation, where allies are compelled to demonstrate their commitment through direct financial contributions. This policy reorientation accelerates European strategic autonomy. While the immediate effect is Europe paying for U.S. weapons, the long-term implication is a forced impetus for greater European defense integration and self-sufficiency. European nations have already been increasing their defense spending and proactively planning for a future with less guaranteed U.S. aid. This new model, by making U.S. weapons available for purchase, encourages Europe to develop its own robust procurement mechanisms and potentially expand its own defense industrial base. Ukraine's most pressing and enduring need remains robust air defense against Russia's escalating missile and drone attacks. The U.S.-made Patriot air-defense system is critical, as it is one of the few systems capable of intercepting high-speed ballistic missiles. These systems are vital for protecting civilian infrastructure and population centers, which have been subjected to relentless Russian bombardment. A critical strategic reality for Ukraine is that not all American weapons are equally replaceable by European alternatives. While Europe is ramping up its own artillery production, the Patriot system's unique counter-ballistic missile capability makes it a requirement that only the U.S. can provide at scale. Europe, at the same time, has demonstrated a clear willingness and increasing capacity to shoulder a greater share of the burden. The European Union has already provided €165 billion in financial assistance and has launched an €800 billion Defense Readiness Plan. Frozen Russian sovereign assets may be used to finance what Ukraine needs. The shift to a foreign military sales model is explicitly intended to invigorate the U.S. defense industrial base. By integrating 'exportability features' into defense systems during the design phase, the U.S. seeks to advance its competitiveness abroad and potentially lower unit costs for both America and its allies. While the foreign military sales process has historically been slow and plagued by delivery backlogs, the new model offers a potential solution. Consistent, large-scale orders from European allies could provide the long-term contract certainty that the U.S. defense industry requires to invest significantly in surge capacity and overcome challenges. This transforms what was previously a 'drain' on American stockpiles, requiring replenishment at taxpayer expense, into a sustained stimulus for U.S. manufacturing, aligning with 'America First' economic principles. This shift is not merely about burden-sharing; it is about recapitalizing and modernizing the U.S. defense industrial base. While immediate fixes for current shortages remain challenging, this strategic reorientation creates a more sustainable industrial ecosystem. Trump's recent rhetoric marks a notable change from his earlier stance, which often appeared conciliatory toward Vladimir Putin. He has recognized that Russia, not Ukraine, is the core problem in negotiations, even threatening tariffs and sanctions on Russia and its trading partners if a peace deal is not reached within 50 days. The reality that Putin is not amenable to a quick 'deal' is now clear. There is now a crucial political opening for continued support to Ukraine, even if the funding mechanism changes. The narrative that Trump desires Ukraine's fall has been refuted. Instead, Trump is committed to ending the war on terms that align with his administration's interests. This represents a significant psychological advantage for Ukraine, as it lessens the fear of a complete U.S. abandonment.
Business Wire
a minute ago
- Business Wire
Pathward Secures a Spot on the 2025 Monitor 100
SIOUX FALLS, S.D.--(BUSINESS WIRE)--Pathward Financial, Inc. (Nasdaq: CASH) through its subsidiary, Pathward®, N.A. ('bank' or 'Pathward'), announced that it has earned a spot on the 2025 Monitor 100 list. Monitor, a magazine focused on equipment finance, publishes the annual Monitor 100 rankings to recognize and celebrate the top equipment finance and leasing organizations across the nation based on portfolio activity and volume of business each year. The 2025 Monitor 100 list looks at company performance in 2024. 'We're honored to be recognized on the Monitor 100 list for the 13th year in a row,' said Christopher Soupal, Divisional President and Revenue Lending Officer at Pathward. 'Being named to the annual list of top equipment finance companies is a testament to our team that is dedicated to Pathward's purpose of financial inclusion and providing funding solutions to help businesses reach their goals.' Read Pathward's feature on page 28 in the Monitor 100 2025 | Vol. 52 No. 4. In addition to Equipment Finance solutions, Pathward offers Working Capital and Structured Finance solutions as part of our forward-thinking Commercial Finance portfolio. Learn more about our flexible finance capabilities and options for a broad range of industries on our website at About Pathward Financial, Inc. Pathward Financial, Inc. (Nasdaq: CASH) is a U.S.-based financial holding company driven by its purpose to power financial inclusion. Through our subsidiary, Pathward®, N.A., we strive to increase financial availability, choice and opportunity across our Partner Solutions and Commercial Finance business lines. These strategic business lines provide support to individuals and businesses. Learn more at About Pathward® Pathward®, N.A., a national bank, is a subsidiary of Pathward Financial, Inc. (Nasdaq: CASH). Pathward is focused on financial access and strives to increase financial availability, choice and opportunity across our Partner Solutions and Commercial Finance business lines. The strategic business lines provide support to individuals and businesses. Learn more at
Business Wire
a minute ago
- Business Wire
Aditxt's Subsidiary Pearsanta Receives an Invitation to Submit Full Proposal for the U.S. Department of Defense Pilot Award for the Development of its Mitomic® Ovarian Test
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, is pleased to announce that its subsidiary, Pearsanta, Inc. (' Pearsanta'), has received an invitation to submit a full proposal for the Congressionally Directed Medical Research Program's (CDMRP) Ovarian Cancer Research Program ('OCRP') Pilot Award, funded through the U.S. Department of Defense (Funding Opportunity Number: HT942525OCRPPA) for its Mitomic® Ovarian Test ('MOT™'), a novel blood-based diagnostic for ovarian cancer. Pearsanta's Mitomic® technology is a platform that is designed to use mitochondrial DNA to identify biomarkers and to develop tests for early detection of cancer and other diseases. Pearsanta is currently conducting clinical validation of the first two tests that have been developed based on this technology for early detection of prostate cancer and endometriosis. MOT™ will potentially be another blood-based test to be added to the Company's product pipeline designed for earlier detection of ovarian cancer. Ovarian cancer currently has a poor prognosis due to the fact that it is typically detected in later stages. Early detection of ovarian cancer can potentially improve the outcomes for women who face this terrible disease. Pearsanta submitted a pre-proposal on June 10, 2025, which was favorably reviewed for its scientific merit, level of innovation, alignment with OCRP Areas of Interest, and potential impact. The full proposal, titled 'Mitochondrial DNA Deletions in Plasma as a Diagnostic Aid for Ovarian Cancer,' is currently under development and will be submitted by the September 11, 2025, deadline. The OCRP Pilot Award offers up to $350,000 over two years to support high-risk, high-reward research that could lead to critical discoveries and advance the field of ovarian cancer diagnostics and treatment. Pearsanta's proposed project aligns directly with the program's priority to 'identify and develop new strategies for screening, early-stage detection, accurate diagnosis, and prognosis.' 'Early detection is one of the greatest unmet needs in ovarian cancer care,' said Chris Mitton, President of Pearsanta. 'Our Mitomic® Ovarian Test has the potential to enable timely, more effective interventions, improve survival rates, and ultimately save lives. If successful, it could change the standard of care by offering a simple blood test that detects ovarian cancer at an earlier, more treatable stage—potentially improving survival and quality of life for women.' The study aims to further develop and validate the MOT™ at Pearsanta's Richmond, Virginia CLIA/CAP laboratory and monitoring facility in preparation for commercial launch as a laboratory-developed test (LDT). Plans include a prospective, multi-center clinical study to collect and analyze blood samples from women undergoing evaluation for suspected ovarian cancer. 'Pearsanta's continued progress is a powerful validation of our mission to accelerate promising health innovations with real-world impact,' said Amro Albanna, CEO of Aditxt. 'We believe the Mitomic® platform has the potential to transform how diseases are detected and managed. Supporting the development of the MOT™ reflects our broader strategy to Acquire high-potential innovations, Build them into clinically and commercially viable solutions, and Capitalize their value to drive scalable deployment globally. About Pearsanta Pearsanta is at the forefront of precision health, focusing on early cancer detection through advanced diagnostic technologies. Its proprietary Mitomic Technology Platform leverages the unique properties of mitochondrial DNA to detect cancer and other diseases with high accuracy via non-invasive, blood-based liquid, biopsy tests. Pearsanta's asset portfolio also includes a range of other innovative diagnostic technologies, all aimed at transforming early disease detection and monitoring, enabling more informed treatment decisions and ultimately improving patient outcomes. For more information, please visit About Aditxt, Inc. Aditxt, Inc. is a social innovation platform accelerating promising health innovations. Aditxt's ecosystem of research institutions, industry partners, and shareholders collaboratively drives their mission to "Make Promising Innovations Possible Together." The innovation platform is the cornerstone of Aditxt's strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder's voice is heard and valued, and empowers collective progress. The Company currently operates two programs focused on immune health, and precision health. Through the proposed acquisition of Evofem under the July 2024 Amended and Restated Merger Agreement between Evofem, Aditxt and Adifem, Inc., as amended (the "A&R Merger Agreement"), Aditxt aims to introduce an additional program dedicated to women's health. The companies are working toward a targeted close in the second half of 2025. The closing of the transaction with Evofem is subject to several conditions, including but not limited to approval of the transaction by Evofem's shareholders and Aditxt raising sufficient capital to fund its obligations at closing. These obligations include cash payments of approximately $17 million for Evofem, which includes approximately $15.0 million required to satisfy Evofem's senior secured noteholder; should Aditxt fail to secure these funds, Evofem's senior secured noteholder is expected to seek to prevent the closing of the merger with Evofem. No assurance can be provided that all of the conditions to closing will be obtained or satisfied, or that the transaction will ultimately close. Forward-Looking Statements This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "achieving," "advancing", "aim," "are working to," "believe," "completing," "continue," "could," "design," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "seek," "should," "suggest," "strategy," "target," "will," "would," and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include but are not limited to the potential success of Pearsanta's proposal for the U.S. Department of Defense Pilot Award; the ability of Pearsanta's Mitomic technology, including the MOT, to detect cancer or other diseases; Pearsanta's ability to commence in-human clinical trials on the proposed timeline, if at all; Aditxt's ability to successfully execute its mission to accelerate and monetize promising health innovations, and magnitude thereof; Aditxt's ability to complete the proposed initial public offering of Pearsanta on the proposed timeline, if at all; and Aditxt's ability to close the planned acquisition of Evofem, including to meet all closing conditions, and the timing thereof. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements are disclosed in each company's SEC filings, including Aditxt's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 31, 2025, and any subsequent Form 10-Q filings. All forward-looking statements are expressly qualified in their entirety by such factors. Aditxt undertakes no duty to update any forward-looking statement except as required by law. For more information, please visit Follow Aditxt on:
